ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 89 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $432,532 | +0.0% | 71,730 | +84.9% | 0.00% | – |
| Q1 2024 | $432,509 | -27.9% | 38,790 | -3.7% | 0.00% | – |
| Q4 2023 | $599,918 | +210.2% | 40,290 | 0.0% | 0.00% | – |
| Q3 2023 | $193,392 | -33.3% | 40,290 | +4.4% | 0.00% | – |
| Q2 2023 | $289,736 | +113.7% | 38,580 | +28.6% | 0.00% | – |
| Q1 2023 | $135,600 | -57.8% | 30,000 | +5.3% | 0.00% | – |
| Q4 2022 | $321,195 | +32.2% | 28,500 | +12.2% | 0.00% | – |
| Q3 2022 | $243,000 | +8.0% | 25,400 | -8.6% | 0.00% | – |
| Q2 2022 | $225,000 | -35.0% | 27,800 | +35.6% | 0.00% | – |
| Q1 2022 | $346,000 | -21.5% | 20,500 | 0.0% | 0.00% | – |
| Q4 2021 | $441,000 | -74.6% | 20,500 | -12.8% | 0.00% | -100.0% |
| Q3 2021 | $1,736,000 | +35.1% | 23,500 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,285,000 | -22.2% | 23,500 | +4.9% | 0.00% | 0.0% |
| Q1 2021 | $1,652,000 | +29.5% | 22,400 | +51.4% | 0.00% | 0.0% |
| Q4 2020 | $1,276,000 | – | 14,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $58,490,548 | 25.26% |
| Vivo Capital, LLC | 4,220,048 | $25,446,889 | 2.35% |
| MPM BioImpact LLC | 2,180,864 | $13,150,610 | 2.04% |
| Vestal Point Capital, LP | 3,600,000 | $21,708,000 | 1.62% |
| Redmile Group, LLC | 4,036,451 | $24,339,800 | 1.47% |
| Privium Fund Management B.V. | 396,966 | $2,270,646 | 0.58% |
| Paradigm Biocapital Advisors LP | 1,575,605 | $9,500,898 | 0.36% |
| Nan Fung Group Holdings Ltd | 41,950 | $252,959 | 0.27% |
| Orbimed Advisors | 1,894,462 | $11,423,606 | 0.23% |
| Affinity Asset Advisors, LLC | 100,000 | $603,000 | 0.07% |